Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 12451-12460 Newer>

The Motley Fool February 15, 2006 Tim Beyers	McDonald's: Allergic to Common Sense The fast-food leader admits to a labeling gaffe, but still isn't forthcoming with consumers. Less important, but still significant for investors, is what this all means for the restaurant's healthy choices strategy.
The Motley Fool February 15, 2006 W.D. Crotty	Motorola's Making Sense The cell phone giant announces a hush-hush strategy for its new products. Investors would be well served to step back, look at the industry, and consider what Motorola is doing.
The Motley Fool February 15, 2006 Nathan Slaughter	Why I Failed as a Broker Even well-intentioned brokers with a vested interest in seeing their clients succeed will never have as much at stake as you do when it comes to your own money and financial independence.
The Motley Fool February 15, 2006 Stephen D. Simpson	Pediatrix: Time to Grow Up After success in the neonatal market, it may be time for this company to expand. Pediatrix is still a strong player, but the stock isn't quite as appealing as it was 10% or 20% ago.
The Motley Fool February 15, 2006 Seth Jayson	3 Things You Must Know A checklist for stock market success, courtesy of our Secretary of Defense.
The Motley Fool February 15, 2006 Stephen D. Simpson	An Income Twofer in Energy Penn Virginia isn't cheap, but it's a high-quality income play on two vital energy sources.
The Motley Fool February 15, 2006 Tim Beyers	Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's buying now? Boston Scientific... Franklin Bank... Fossil... Gartner... iPass...
The Motley Fool February 15, 2006 Stephen D. Simpson	Ride Out the Cycle With PACCAR? An upcoming drop in orders will challenge all truck companies. It will take a fair amount of patience to hang onto these shares for the next couple of years.
The Motley Fool February 15, 2006 Stephen D. Simpson	Total Tops the Charts Production growth and good cash flow make this an energy stock worth watching.
The Motley Fool February 15, 2006 Stephen D. Simpson	A Play on the Building Blocks of R&D Sigma-Aldrich might be suitable for those looking to play biological R&D without picking a specific pharma or biotech stock.
<Older 12451-12460 Newer> Return to current articles.